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Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MinnesotaABSTRACT We have used electron paramagnetic resonance (EPR) to probe the homo- and heterooligomeric interactions of
reconstituted sarcoplasmic reticulum Ca-ATPase (SERCA) and its regulator phospholamban (PLB). SERCA is responsible for
restoring calcium to the sarcoplasmic reticulum to allow muscle relaxation, whereas PLB inhibits cardiac SERCA unless phos-
phorylated at Ser16. To determine whether changes in protein association play essential roles in regulation, we detected the
microsecond rotational diffusion of both proteins using saturation transfer EPR. Peptide synthesis was used to create a fully
functional and monomeric PLB mutant with a spin label rigidly coupled to the backbone of the transmembrane helix, while
SERCA was reacted with a Cys-specific spin label. Saturation transfer EPR revealed that sufficiently high lipid/protein ratios
minimized self-association for both proteins. Under these dilute conditions, labeled PLB was substantially immobilized after
co-reconstitution with unlabeled SERCA, reflecting their association to form the regulatory complex. Ser16 phosphorylation
slightly increased this immobilization. Complementary measurements with labeled SERCA showed no change in mobility after
co-reconstitution with unlabeled PLB, regardless of its phosphorylation state. We conclude that phosphorylating monomeric PLB
can relieve SERCA inhibition without changes in the oligomeric states of these proteins, indicating a structural rearrangement
within the heterodimeric regulatory complex.INTRODUCTIONMuscle relaxation is induced by the active transport of the
divalent calcium ion (Ca2þ) from the cytoplasm into the
sarcoplasmic reticulum (SR). The SR Ca2þ-ATPase
(SERCA) is a 994-residue enzyme that transports two
Ca2þ into the SR lumen per ATP hydrolyzed (Fig. 1, left)
(1), resulting in muscle relaxation. In cardiac and slow-
twitch muscle, SERCA activity is allosterically regulated
by phospholamban (PLB) (2), a 52-residue membrane
protein consisting of a 30-residue transmembrane helix
and a 16-residue cytosolic helix connected by a short, flex-
ible loop (3) (Fig. 1, right). PLB inhibits SERCA by
decreasing its apparent Ca2þ affinity (increasing KCa) (4).
SERCA inhibition is relieved physiologically either by
micromolar [Ca2þ] or through PLB phosphorylation at
Ser16 by protein kinase A (5), and can also be relieved by
PLB point mutations (6–8).
The regulatory mechanism of the SERCA-PLB complex
has considerable therapeutic relevance, because inadequate
calcium transport has been strongly linked to heart failure
(9). Emerging treatments aim to improve cardiac perfor-
mance by increasing SERCA activity through increased
SERCA expression (10), allosteric activation of SERCA
by small molecules (11), or reduced PLB inhibitory potency
(12,13). Elucidating this mechanism would provide a road-
map for the rational design of PLB mutants and drugs
designed to activate SERCA.Submitted April 4, 2012, and accepted for publication August 9, 2012.
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0006-3495/12/09/1370/9 $2.00However, this regulatory mechanism remains controver-
sial. Cross-linking (14) and immunoprecipitation (15)
studies suggest that dissociation of the SERCA-PLB com-
plex is required (Fig. 2, Dissociation Model). However,
spectroscopic studies suggest that PLB remains bound to
SERCA after activation by Ser16 phosphorylation (16–18),
Ca2þ addition (19), or PLB loss-of-function mutations
(13,18), indicating that a structural rearrangement within
the complex can relieve inhibition (Fig. 2, Subunit Model).
Other studies have also identified multiple PLB conforma-
tions within the regulatory complex that correlate with
different inhibitory states (17,20).Oligomeric interactions
Distinguishing these regulatory mechanisms is made more
difficult by the variety of protein-protein interactions in
this system. Although the fundamental inhibitory complex
is proposed to be a SERCA-PLB heterodimer (2,21,22)
(Fig. 2, center), both proteins form homooligomers that
can affect SERCA function (Fig. 2). SERCA may form
functioning dimer and trimer states (23,24), while larger
aggregates lead to inhibition (25,26). Numerous studies
have examined the oligomeric state of SERCA in native
(27–29) and reconstituted (25) membranes, and several
have investigated the role of the lipid/protein molar ratio
(L/P) in modulating SERCA aggregation (26,30,31), all
based on the proportionality between oligomeric size and
rotational correlation time (32).
In cardiac SR, SERCA inhibition and aggregation are
both relieved by micromolar Ca2þ or PLB phosphorylation
(33). Native PLB equilibrates between monomers andhttp://dx.doi.org/10.1016/j.bpj.2012.08.032
FIGURE 2 Oligomeric interactions of SERCA and PLB. Both proteins
have homooligomeric interactions (left), and bind to form an inhibited
SERCA-PLB complex (center). Phosphorylation of PLB relieves inhibition
(right), which may occur through dissociation of the complex (Dissociation
Model), or a structural rearrangement within the complex (Subunit Model).
FIGURE 1 Structural models of SERCA (left, crystal structure 1IWO
(76)) and monomeric PLB (right, hybrid NMR structure 2KB7 (77)). All
experiments in this study were conducted with the monomeric form of
PLB. The amino-acid TOAC (bottom right), containing a nitroxide spin
label rigidly coupled to the a-carbon, is incorporated at position 36 (shaded
star) on PLB; PLB residues 41 and 46 (shaded) are mutated to Phe and Ala.
For unlabeled PLB, position 36 is Ala. For spin-labeled SERCA, MSL
(top right) is attached at Cys344/Cys364 (solid star) (78).
Oligomeric Interactions of SERCA and PLB 1371homopentamers, and the latter can be destabilized by muta-
tion (typically leading to increased SERCA inhibition) or
stabilized by phosphorylation (leading to decreased SERCA
inhibition). Thus, inhibition depends, at least in part, on the
concentration of PLB monomer (21). To simplify analysis
and focus on SERCA-PLB interactions, we have used 1),
a monomeric PLB mutant, C36A/C41F/C46A-phospholam-
ban (AFA-PLB, referred to below as PLB) (34) in which
oligomerization is eliminated by replacing Cys residues
36, 41, and 46 with Ala, Phe, and Ala, respectively, and
2), sufficiently high L/Ps to minimize self-association of
both SERCA and PLB. Thus, we are able to focus solely
on the heterodimeric interactions between these two
proteins.
In this study, we have characterized the heterooligomeri-
zation of PLB and SERCA using electron paramagnetic
resonance (EPR), while minimizing the homooligomeriza-
tion of both proteins. Rotational motions detected by EPR
can be sensitive to oligomeric interactions, because the rota-
tional correlation time (tR) of the spin-labeled protein is
proportional to the protein’s transmembrane volume (32).
However, conventional EPR is sensitive only to correlation
times in the nanosecond range, which is appropriate for
rotation of aqueous proteins, but not membrane-embedded
proteins, where the viscosity (and thus tR) is orders-
of-magnitude greater. Even in fluid lipid bilayers, tR values
for most integral membrane proteins are in the microsecond
range.These slow rotational motions are best measured by
saturation transfer EPR (STEPR) (35,36), which requires
the use of spin probes that are immobilized on the labeled
protein. In this study, PLB rotational motion was detected
by incorporating the spin label 2,2,6,6-tetramethylpiperi-
dine-1-oxyl-4-amino-4-carboxylic acid (TOAC) into the
peptide backbone at position 36 in the transmembrane helix
(Fig. 1), while SERCA rotational dynamics was detected
after covalent reaction with a maleimide spin label, 4-mal-
eimido-TEMPO (MSL). Both labels have been shown to
be rigidly attached to their respective proteins, making
them sensitive to rigid-body rotational diffusion that directly
reflects the size of the oligomeric complex (27,37). We used
STEPR to first find conditions where homooligomerization
was minimized, and then to detect the formation of
SERCA-PLB heterooligomers so as to discriminate between
the Dissociation Model and the Subunit Model (see Fig. 2).METHODS
Peptide synthesis
C36TOAC, C41F, C46A, PLB (36-TOAC-AFA-PLB) and C36A,
C41F, C46A PLB (AFA-PLB) were synthesized as described previously
(37–39). Fmoc-TOAC was purchased from Toronto Research Chemicals
(North York, Ontario, Canada) and Fmoc-protected amino acids were
purchased from EMD Chemicals (Philadelphia, PA). Peptides were purified
by reverse-phase HPLC on a preparative C8 column (Grace Vydac,
Hesperia, CA) using H2O þ 0.1% trifluoroacetic acid and isopropanol as
mobile phases. Peptides were characterized by mass spectrometry and
sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Protein concentrations were quantified using a bicinchoninic-acid assay
(Thermo Fisher Scientific, Rockford IL).SERCA purification and spin labeling
SR vesicles were prepared from rabbit fast-twitch muscle (40), then resus-
pended to 25 mg/mL total protein in SR buffer (30 mM 3-(n-morpholino)
propanesulfonic acid (MOPS), 0.3 M sucrose, pH 7.0). SERCA was puri-
fied by reactive red chromatography (41), omitting reducing agents. For
spin labeling, SERCA was diluted to 10 mg/mL with SR buffer, to which
300 mM MSL was added from a 50 mM stock in dimethylformamide.
After stirring 1 h at 25C, labeled vesicles were diluted 10-fold in SRBiophysical Journal 103(6) 1370–1378
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MSL. The resulting pellet was resuspended in SR buffer and purified as
above. Protein concentrations were quantified using a bicinchoninic-acid
assay.Reconstitution of SERCA and PLB
Functional reconstitution of SERCA and PLB was carried out as described
previously, using 4:1 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)/
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (mol/mol) to
yield unilamellar vesicles that are optimal for reproducing physiological
SERCA-PLB regulatory function (42,43). These vesicles have an average
diameter of 100 nm (43) and thus rotate too slowly to affect our saturation
transfer EPR spectra (27,45). Final buffer composition of EPR samples was
50 mM MOPS, 50 mM KCl, 5 mM MgCl2, 0.5 mM ethylene glycol-bis(2-
aminoethylether)-n,n,n0,n0-tetraacetic acid (EGTA), 210 mMCaCl2, pH 7.0,
resulting in pCa 6.5 to give optimal regulation of SERCA by PLB (19).
Identical buffer conditions were used in functional assays, except that
[CaCl2] was varied. An enzyme-coupled ATPase assay was used to measure
the Ca-dependence of SERCA activity as described previously in Lockamy
et al. (13) and Reddy et al. (42).
As in previous publications from our laboratory, EPR experiments were
performed at 4C to maintain protein stability during lengthy STEPR
experiments, while functional measurements were performed at 25C to
enhance SERCA activity and permit comparison to published work. PLB
inhibitory potency is only weakly dependent on temperature (46). For phos-
phorylation, the PLB/lipid/detergent mixture (containing 20 mM PLB,
before SERCA addition) was incubated 2 h at 25C with 200 IU/mL bovine
protein kinase A catalytic subunit (Sigma, St. Louis, MO) and 1 mM
MgATP. Complete PLB phosphorylation (>92%) was confirmed by quan-
titative Western blotting (47) using 10–20% tris-tricine gels (Bio-Rad,
Hercules, CA).FIGURE 3 Ca-dependence of ATPase activity. Samples were reconsti-
tuted at 700 lipids/SERCA and 10 PLB/SERCA (mol/mol). ATP turnover
was measured at 25C, fit by Eq. 1, and normalized to Vmax. SERCA-
only controls (circles) were compared to samples containing PLB (solid
squares), 36-TOAC-PLB (solid diamonds), and their pSer16 counterparts
(open squares and diamonds). pKCa values obtained from the fits were
used to quantify SERCA inhibition, and are summarized in Table S1 in
the Supporting Material.EPR spectroscopy and data analysis
Before EPR experiments, samples were centrifuged 1 h at 200,000  g
(4C) and the pellets resuspended in minimal buffer; 40 mL samples were
loaded into 22-gauge Teflon tubing (Amazon Supply, Miami Lakes, FL)
threaded through a glass capillary (Wiretrol; Drummond Scientific
Company, Broomall, PA) flame-sealed at one end. The Teflon tubing
extended 1 cm from the end of the capillary and was plugged with Critoseal
(Krackeler Scientific, Albany, NY). Spectra were acquired at X-band (9.5
GHz) with an EleXsys E500 spectrometer equipped with the ER 4122
SHQ cavity (Bruker BioSpin, Billerica, MA). Temperature was maintained
at 45 0.2C with a quartz Dewar insert and a nitrogen-gas-flow tempera-
ture controller. Spectra were acquired after sample deoxygenation under
nitrogen gas (~1 h) to eliminate the dependence of spectra on oxygen acces-
sibility (48). Microwave field amplitude H1 (G) was calibrated with a solu-
tion of 0.9 mM PADS, 50 mM K2CO3 (48).
Spectral acquisition parameters were set according to Squier and Thomas
(48). Conventional (V1, first harmonic, in-phase) EPR spectra were
acquired with H1¼ 0.14 G microwave field amplitude, 100 kHz modulation
frequency, 2 G modulation amplitude, and 120 G sweep width. V1 spectra
used for normalization were acquired as above except that H1 was set to
0.032 G. STEPR (V2
0, second harmonic, out-of-phase) spectra were
acquired with 50 kHz modulation frequency, 5 G modulation amplitude,
and 120 G sweep width. After null phase determination by minimizing
the signal at nonsaturating microwave intensity (H1 ¼ 0.032 G), H1 was
increased to 0.25 G and the V2
0 spectrum recorded. All EPR spectra were
baseline-corrected and then normalized, either to !!V1 (conventional
EPR) or to !!V1 / H1 for H1 ¼ 0.032 G (STEPR). V1 EPR spectra near
the slow-motion limit were analyzed by evaluating lineshape features DL
0
(the outer half-width of the low-field line, which increases with spin-spin
interaction and rotational motion) and 2Tjj0 (the splitting between outerBiophysical Journal 103(6) 1370–1378extrema, which decreases with rotational motion but not with spin-spin
interaction) (49,50).
For V2
0 spectra, effective rotational correlation times were calculated
from an integrated intensity parameter (IST), using a correlation plot created
from MSL-hemoglobin samples in glycerol (48). IST reports an effective
rotational correlation time that is minimally sensitive to modulation phase
errors and thus provides greater precision than provided by lineshape
parameters (48).
Data plots were produced with Origin 8.1 (OriginLab, Northampton,
MA). Error bars are mean 5 SE (n ¼ 3–5). When no error bar is visible,
this indicates that SE is smaller than the plotted symbol.RESULTS
Functional assays
To confirm that 36-TOAC-PLB retained regulatory func-
tion, we reconstituted it with SERCA into 4:1 (mol/mol)
1,2-dioleoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPC/DOPE) vesicles at
700 lipids/SERCA (mol/mol) and measured Ca-dependent
ATPase activity using a coupled-enzyme assay (42). Results
were fit by the Hill equation,
V ¼ Vmax½1þ 10nðpKCapCaÞ; (1)
where V is the ATPase rate, Vmax is the ATPase rate at satu-
rating [Ca2þ], n is the Hill coefficient, and pKCa is the pCa
(log10[Ca2þ]) where activity is half-maximal. PLB inhib-
itory potency, defined as the decrease in pKCa, was indistin-
guishable between our spin-labeled construct and unlabeled
PLB controls (Fig. 3). At 10 PLB/SERCA, where inhibition
Oligomeric Interactions of SERCA and PLB 1373is maximal, pKCa shifted from 6.485 0.01 to 6.005 0.01
(inhibitory potency ¼ 0.48 5 0.02). When PLB was com-
pletely phosphorylated (pPLB, >92%), inhibition was
partially reversed, increasing pKCa to 6.30 5 0.01 (inhibi-
tory potency ¼ 0.18 5 0.02) and restoring SERCA Ca2þ
sensitivity to the same extent as phosphorylating unlabeled
PLB (Fig. 3). At 0.5 PLB/SERCA, matching the conditions
of some experiments below, the inhibitory potency of
36-TOAC-PLB was 0.28 5 0.03 (unphosphorylated) and
0.12 5 0.04 (phosphorylated). These results, including
the partial reversal of inhibition by phosphorylation, are
similar to those reported previously for other PLB deriva-
tives (17,37) and demonstrate that 36-TOAC-PLB regulates
SERCA normally. We also used functional assays to deter-
mine whether reacting SERCAwith MSL affected its inter-
action with PLB. Although MSL decreased Vmax by ~30%
as reported previously (29), pKCa regulation by PLB was
unaltered, indicating that the label does not perturb regula-
tory interactions between the two proteins.Monomeric mutant AFA-PLB does not aggregate
Our goal was to find conditions in which self-association is
minimized for both PLB and SERCA.We used conventional
and saturation transfer EPR to examine spin-labeled PLB or
SERCA reconstituted at several L/P. Conventional EPR of
36-TOAC-PLB detected only a marginal decrease in outer
splitting (2Tjj0, Fig. 4 a) with increasing L/P, indicating littleFIGURE 4 Dependence of conventional EPR spectra of 36-TOAC-PLB
on lipid/protein ratio. (a) Spectra of 36-TOAC-PLB reconstituted at 200–
1000 L/P. (b) Outer splitting (2Tjj0, triangles) and low-field outer linewidth
(DL
0, squares) as a function of L/P. The vertical scales were set so that
a change in rotational motion would yield changes inDL
0 and 2Tjj0 of similar
magnitude (but opposite sign) (49,50). STEPR spectra are given in Fig. S3.or no change in nanosecond rotational dynamics. However,
lipid dilution did lead to a substantial decrease in the line-
width (DL
0) (Fig. 4 b), which could arise from decreased
nanosecond rotational mobility (49,50), but this is inconsis-
tent with the lack of increased splitting (Fig. 4 b). Thus, the
linewidth decrease is due to decreased dipolar broadening
from spin-spin interactions, but the observed broadening is
precisely that expected for a random two-dimensional
arrangement of monomers in the membrane (51), and would
be much greater if PLB oligomers were present, as demon-
strated by Fig. S1 and Fig. S2 in the Supporting Material.
STEPR spectra support this interpretation (see Fig. S3).
Thus, this PLB construct remains predominantly mono-
meric at all L/P tested here.SERCA does not aggregate above 600 L/P
We conducted similar lipid-dilution experiments with MSL-
SERCA. Conventional EPR spectra (see Fig. S4) have no
significant dependence on L/P, confirming the previous
finding that this spin label binds rigidly to SERCA and
undergoes no nanosecond rotational dynamics (27). Thus,
any changes in STEPR spectra (Fig. 5 a) are due to changes
in microsecond rotational motion of SERCA about an axis
perpendicular to the membrane (27). These STEPR spectra
show that the effective rotational correlation time tR
decreases substantially from L/P ¼ 200–600, to a limitingFIGURE 5 STEPR of MSL-SERCA as a function of lipid/protein molar
ratio (L/P). (a) Representative STEPR (V2
0) spectra of reconstituted MSL-
SERCA. (b) Effective rotational correlation times (tR). Conventional EPR
(V1) spectra are given in Fig. S4.
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rotational diffusion of monomeric or dimeric SERCA (28)
based on the Saffman-Delbru¨ck equation (32), which
predicts that tR is proportional to protein transmembrane
volume and lipid viscosity. Assuming a membrane height
of 4 nm (52) and membrane viscosity of 2–5 P (53), the
Saffman-Delbru¨ck model yields correlation times of 2–4 ms
and 8–19 ms for SERCA monomers and dimers, respec-
tively. We conclude that SERCA undergoes concentration-
dependent self-association, but that this dependence is
negligible for L/P > 600, suggesting the presence of stable
SERCA monomers or small oligomers. Therefore, further
experiments were performed at 700 lipids per SERCA to
eliminate the formation of homooligomers, allowing us to
focus on the SERCA-PLB interaction.Effects of phosphorylation and SERCA binding
on rotational dynamics of spin-labeled PLB
We co-reconstituted 36-TOAC-PLB with SERCA to inves-
tigate PLB rotational dynamics within the regulatory
complex, using 700 lipids/SERCA and 0.5 PLB/SERCA
to minimize both homooligomers and unbound PLB.
Conventional EPR spectra of co-reconstituted samples
(PLB þ SERCA, pPLB þ SERCA) and their PLB-only
controls (PLB, pPLB) are all near the rigid limit and are
virtually identical (Fig. 6, a and c), indicating no change
in nanosecond dynamics or self-association of PLB upon
phosphorylation and/or SERCA binding. The V1 EPR
spectra in Fig. 6 a contain subtle shoulders on the low-
and high-field peaks. These could arise from spin-spin inter-
actions (Fig. 5, and see Fig. S1) or the presence of slow
restricted-amplitude rotation (54). However, the V1 spectraFIGURE 6 Effects of Ser16 phosphorylation and SERCA on EPR of 36-
TOAC-PLB. (a) Conventional (V1) EPR spectra and (b) STEPR (V2
0)
spectra of 36-TOAC-PLB as affected by phosphorylation (pPLB) and/or
SERCA (0.5 PLB/SERCA). (c) Outer splitting 2Tjj0 measured from conven-
tional EPR spectra in panel a. (d) Effective rotational correlation times from
STEPR spectra in panel b. Typical normalized spectra are shown in panels
a and b. (Bar graphs in panels c and d show mean5 SE for n¼ 3–5 trials.)
Biophysical Journal 103(6) 1370–1378are not affected by phosphorylation and/or SERCA addi-
tion, so the effects on V2
0 spectra (Fig. 6 b) must arise
from changes in microsecond rotational dynamics.
In contrast to the invariant conventional (V1) spectra
(Fig. 6, a and c), STEPR (V2
0) revealed significant changes
in microsecond dynamics (Fig. 6, b and d). SERCA
decreased PLB mobility substantially, with tR increasing
from 1.95 0.4 ms (PLB) to 5.65 0.2 ms (PLB þ SERCA),
consistent with the large increase in SERCA binding. Ser16
phosphorylation had no significant effect on PLB dynamics
in the absence of SERCA (Fig. 6, b and d), but increased tR
slightly in the presence of SERCA, from 5.6 5 0.2 ms to
6.5 5 0.1 ms (Fig. 6 d). This larger tR is probably not
due to increased binding to SERCA (because that would
increase inhibition) or to increased PLB aggregation
(because that is inconsistent with the V1 spectra in
Fig. 6 a), so it must be due to some structural change of
the SERCA-PLB complex that alters either the tilt of the
PLB TM domain or the frictional interaction of the
SERCA-PLB complex with lipid (55–57). In any case, it
is clear that PLB does not dissociate from SERCA after
phosphorylation, because this would cause a substantial
decrease in the rotational correlation time, making the
blue (pPLB) and purple (pPLB þ SERCA) spectra identical
(Fig. 6, c and d). Indeed, a slight increase in tR was observed
due to phosphorylation (Fig. 6 d), and the blue and purple
spectra are quite different (Fig. 6 c), so Fig. 6 clearly contra-
dicts the Dissociation Model and strongly supports the
Subunit Model (Fig. 2).Rotational dynamics of spin-labeled SERCA
reconstituted with PLB
To determine whether the results of Fig. 6 were affected by
changes in SERCA aggregation, we performed identical
experiments except using MSL-SERCA and unlabeled
PLB. Both V1 (see Fig. S5) and V2
0 (Fig. 7) detect no change
in SERCA rotational dynamics due to PLB or pPLB. The
addition of 0.5 PLB per SERCA should increase the trans-
membrane volume (and thus the rotational correlation
time) by only ~5% (32), within the experimental error of
our measurements (~10%, Fig. 6 d). This indicates thatFIGURE 7 STEPR (V2
0) spectra of MSL-SERCA. Experimental condi-
tions are as in Fig. 6, using MSL-SERCA and unlabeled PLB. Rotational
correlation times did not vary significantly among these samples and
were consistent with the data in Fig. 5 at 700 lipids/SERCA (135 4 ms).
Conventional EPR spectra also showed no significant changes (see Fig. S5).
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turbed by PLB binding or phosphorylation under these
dilute conditions (700 lipids/SERCA and 0.5 PLB/SERCA),
despite substantial functional effects. These findings indi-
cate that regulatory effects of PLB do not arise solely
from modulating SERCA aggregation, although such phos-
phorylation-dependent aggregation does contribute to func-
tional regulation in cardiac SR (33).
Rotational correlation times determined from STEPR
spectra are effective, and depend on several parameters
that are not easily controlled or evaluated, such as probe
orientation relative to the diffusion axis (58) and spin label
environment (48). In addition, it is likely that the TM
domain of PLB has residual small-amplitude rotational flex-
ibility relative to SERCA. These factors probably contribute
to the significant differences between the V1 spectra of
the SERCA-PLB complex with labeled PLB (Fig. 6 a) or
labeled SERCA (see Fig. S5), and to the shorter tR values
determined from V2
0 spectra of the complex with labeled
PLB (Fig. 6 b), compared to labeled SERCA (Fig. 7). There-
fore, our key conclusions come from comparing the V2
0
spectra of a particular spin-labeled protein (36-TOAC-PLB
or MSL-SERCA), as perturbed by factors (protein-protein
interactions, protein concentration, and phosphorylation)
that do not affect the V1 spectra.DISCUSSION
We have used EPR to investigate the tendencies of SERCA
and the monomeric AFA-PLB to form homo- and heteroo-
ligomers in reconstituted membranes. By systematically
varying the lipid/protein molar ratio (L/P), we found that
SERCA self-association occurs at low L/P but is eliminated
for L/P > 600 (Fig. 5), even in the presence of 0.5 PLB/
SERCA (Fig. 7). We also showed that TOAC-labeled PLB
does not self-associate under the conditions of this study
(Fig. 4). Thus, the data in Fig. 6 reflect directly the rotational
dynamics of PLB alone or in complex with SERCA.
Because phosphorylation and SERCA binding caused no
significant effects on PLB nanosecond dynamics as detected
by conventional EPR (Fig. 6, left), the changes in STEPR
(Fig. 6, right) are due to microsecond rigid-body dynamics
of PLB. Thus, SERCA does immobilize PLB by binding it,
but phosphorylation does not dissociate PLB from SERCA,
supporting the Subunit Model (Fig. 2, bottom right).AFA-PLB is monomeric in lipid bilayers at high
L/P, even after phosphorylation
Although the null-Cys PLB mutant AAA-PLB, similar to
AFA-PLB, was found previously to be monomeric by
SDS-PAGE (38,59), solid-state NMR studies suggested
that AAA-PLB is substantially aggregated in reconstituted
membranes at the extremely low L/P value of 20 (60). 36-
TOAC-AFA-PLB shows substantial broadening of the V1spectrum at 20 L/P, consistent with aggregation (see
Fig. S1), along with dramatic effects on the V2
0 spectrum
(see Fig. S2), showing that PLB aggregation is detectable
if present. In contrast, our EPR experiments performed
between 200 and 1000 L/P did not reveal significant PLB
aggregation (Fig. 4). This is the most direct demonstration
to date that AFA-PLB behaves as a monomer in reconsti-
tuted bilayers, whether phosphorylated or not. In previous
studies, it was shown that the pentameric propensity of
wild-type PLB increases with phosphorylation (21), and
that SERCA preferentially binds to the PLB monomer
(61). Thus, it remains likely that the decrease in PLB mono-
mer concentration due to phosphorylation plays a significant
role in relieving SERCA inhibition (21,62). However, our
results show that some relief of inhibition by phosphoryla-
tion occurs even under conditions where PLB oligomers
do not form.SERCA self-association occurs only at low L/P
and is not induced by PLB at high L/P
The oligomeric state of SERCA for optimal function has
been postulated to range from monomeric to tetrameric
(24,28,63–65), whereas larger aggregates have been
shown to decrease SERCA activity, whether induced by
cross-linking (66), cationic peptides (67,68), cationic local
anesthetics (69), mismatch in lipid bilayer thickness
(70), small-molecule SERCA inhibitors (23,71), or PLB
(33,72). Most importantly, inhibition relief in cardiac SR
by either Ca2þ or phosphorylation correlates with decreased
SERCA aggregation (33). This study does not contradict
these findings; SERCA aggregation probably plays a signif-
icant physiological role in both skeletal and cardiac SR.
However, our results show that at low protein concentrations
in the membrane (at high L/P), significant changes in
SERCA inhibition by PLB occur without significant
changes in SERCA aggregation (Fig. 7).Binding of TOAC-spin-labeled PLB to SERCA
is clearly detected by STEPR
STEPR shows that reconstitution with SERCA decreases
the microsecond mobility of 36-TOAC-AFA-PLB substan-
tially, consistent with binding (Fig. 6, b and d), whereas
conventional EPR detects no change in nanosecond motion
or PLB aggregation. This complex formation is consistent
with FRET from SERCA to PLB in a similar reconstituted
system (20).Phosphorylation causes a structural change in
the SERCA-PLB complex, not dissociation
Phosphorylation of SERCA-bound PLB at Ser16 does not
increase its rotational mobility, and thus does not dissociate
it from SERCA under conditions of our study (Fig. 6). InBiophysical Journal 103(6) 1370–1378
1376 James et al.fact, an increase in the effective rotational correlation time is
observed, indicating a structural change in the SERCA-PLB
complex that decreases mobility or changes the tilt of the
PLB TM domain. This result supports the Subunit Model
(Fig. 2, bottom right), though future studies are needed to
characterize the structural change. Because the concentra-
tions of SERCA and PLB, as well as the PLB/SERCA ratio,
are much higher in cardiac SR than in the samples consid-
ered here, it is unlikely that phosphorylation of PLB causes
significant dissociation under physiological conditions.
Whereas previous studies have found that PLB is in
dynamic equilibrium between free and SERCA-bound
states (13,73), our data indicate that PLB phosphorylation
does not perturb this binding equilibrium significantly.
This study used the SERCA1a isoform from skeletal SR.
There is no known difference between the functional or
physical interaction of PLB with SERCA1a and SERCA2a
(62,74,75), but future studies with the SERCA2a isoform
will be needed to rule this out. Previous studies using spin
or fluorescent probes of phosphorylated PLB interacting
with SERCA are consistent with the conclusions of this
study (16–18). However, to our knowledge, this is the first
study of the SERCA-PLB interaction using a probe rigidly
coupled to the transmembrane domain of PLB, thus report-
ing reliably the rotational mobility of PLB and showing that
Ser16 phosphorylation does not dissociate the inhibitory
transmembrane domain (38) of PLB from SERCA.CONCLUSIONS
We have used STEPR to detect the microsecond rotational
mobilities of SERCA and AFA-PLB in reconstituted
membranes, providing direct insight into their oligomeric
interactions, as perturbed by phosphorylation. At L/P R
600 and PLB/SERCA ¼ 0.5, SERCA does not change its
state of self-association due to PLB or pPLB, both of which
are strongly immobilized by SERCA binding. Under these
conditions, relief of SERCA inhibition must be due to
a structural change within the SERCA-PLB complex, not
to dissociation of the complex.SUPPORTING MATERIAL
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